| High-dose atorvastatin after stroke or transient ischemic attack P Amarenco, J Bogousslavsky, A Callahan, LB Goldstein, M Hennerici, ... New England Journal of Medicine 355 (6), 549-559, 2006 | 3889* | 2006 |
| Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ... New England Journal of Medicine 379 (22), 2097-2107, 2018 | 2635 | 2018 |
| High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial TR Pedersen, O Faergeman, JJP Kastelein, AG Olsson, MJ Tikkanen, ... Jama 294 (19), 2437-2445, 2005 | 2218 | 2005 |
| HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events P Barter, AM Gotto, JC LaRosa, J Maroni, M Szarek, SM Grundy, ... New England journal of medicine 357 (13), 1301-1310, 2007 | 2126 | 2007 |
| Sotagliflozin in patients with diabetes and recent worsening heart failure DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ... New England journal of medicine 384 (2), 117-128, 2021 | 1420 | 2021 |
| Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment JJP Kastelein, WA Van Der Steeg, I Holme, M Gaffney, NB Cater, P Barter, ... Circulation 117 (23), 3002-3009, 2008 | 986* | 2008 |
| Sotagliflozin in patients with diabetes and chronic kidney disease DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ... New England Journal of Medicine 384 (2), 129-139, 2021 | 865 | 2021 |
| ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ... N Engl J Med 379 (22), 2097-2107, 2018 | 650 | 2018 |
| High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study S Kinlay, GG Schwartz, AG Olsson, N Rifai, SJ Leslie, WJ Sasiela, ... Circulation 108 (13), 1560-1566, 2003 | 585 | 2003 |
| Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial GG Schwartz, L Bessac, LG Berdan, DL Bhatt, V Bittner, R Diaz, ... American heart journal 168 (5), 682-689. e1, 2014 | 565 | 2014 |
| Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study LB Goldstein, P Amarenco, M Szarek, A Callahan III, M Hennerici, ... Neurology 70 (24_part_2), 2364-2370, 2008 | 547 | 2008 |
| Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in … P Amarenco, LB Goldstein, M Szarek, H Sillesen, AE Rudolph, ... Stroke 38 (12), 3198-3204, 2007 | 462 | 2007 |
| Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome VA Bittner, M Szarek, PE Aylward, DL Bhatt, R Diaz, JM Edelberg, Z Fras, ... Journal of the American College of Cardiology 75 (2), 133-144, 2020 | 375* | 2020 |
| LXR/ApoE activation restricts innate immune suppression in cancer MF Tavazoie, I Pollack, R Tanqueco, BN Ostendorf, BS Reis, ... Cell 172 (4), 825-840. e18, 2018 | 373 | 2018 |
| High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in … S Tsimikas, JL Witztum, ER Miller, WJ Sasiela, M Szarek, AG Olsson, ... Circulation 110 (11), 1406-1412, 2004 | 347 | 2004 |
| High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in … S Tsimikas, JL Witztum, ER Miller, WJ Sasiela, M Szarek, AG Olsson, ... Circulation 110 (11), 1406-1412, 2004 | 347 | 2004 |
| Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients CB Newman, G Palmer, H Silbershatz, M Szarek The American journal of cardiology 92 (6), 670-676, 2003 | 300 | 2003 |
| Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients C Newman, J Tsai, M Szarek, D Luo, E Gibson The American journal of cardiology 97 (1), 61-67, 2006 | 284 | 2006 |
| High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial AG Olsson, GG Schwartz, M Szarek, WJ Sasiela, MD Ezekowitz, P Ganz, ... European heart journal 26 (9), 890-896, 2005 | 276 | 2005 |
| High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial AG Olsson, GG Schwartz, M Szarek, WJ Sasiela, MD Ezekowitz, P Ganz, ... European heart journal 26 (9), 890-896, 2005 | 275 | 2005 |
Ph.Gabriel STEGUniversité de Paris, Paris, FranceVerified email at aphp.fr
